



UK Interdisciplinary
Breast Cancer
Symposium 2020

the **icc**
birmingham

INTERNATIONAL CONVENTION CENTRE, BIRMINGHAM
Monday 27th – Tuesday 28th January 2020

www.ukibcs.org

MONDAY 27TH JANUARY 2020 - AT A GLANCE

	HALL 1	HALL 5	HALL 8	HALL 11
9.00-9.10	OPENING			
9.10-10.30	Highlights of the last year			
10.30-11.00	KEYNOTE LECTURE Personalised breast radiation therapy – Are we there yet?			
11.00-11.30	COFFEE			
11.30-12.50	Demystifying partial breast irradiation	Big Data in Breast Cancer	Why can't we kill ER+ breast cancer?	Managing the side-effects of endocrine therapy
12.50-14.00	LUNCH & SPONSORED SATELLITE SYMPOSIA			
12.55-13.55		Sponsored symposium: EXACT SCIENCES	Sponsored symposium: ROCHE	Sponsored symposium: PFIZER
14.00-14.30	KEYNOTE LECTURE Treatment-dependent breast tumour evolution			
14.35-15.55	DCIS - risk estimates and management	Special issues in managing metastatic disease	Phenotypic and genotypic heterogeneity	Free Communications I
15.55-16.20	TEA			
16.20-17.40	Managing the axilla	Late recurrence in ER+ disease	Improving breast cancer outcomes by modifying lifestyle	Novel clinical trial design
17.45-18.15	KEYNOTE LECTURE <u>Cridlan Lecture:</u> De-escalation of medical adjuvant therapy			
18.15-19.15	DRINKS RECEPTION AND POSTER JUDGING SESSION 1 (HALL 3)			

MONDAY 27TH JANUARY 2020 - FULL PROGRAMME

9-9.10	OPENING - Hall 1 <i>Professor Mitch Dowsett & Baroness Delyth Morgan</i>			PARALLEL SESSIONS
9.10-10.30	Highlights of the last year - Hall 1 Chairs: <i>Julia Gee & Andrew Tutt</i>			
	Basic Research <i>Ingunn Holen</i> Translational Research <i>Nick Turner</i> Primary disease <i>Andrew Wardley</i> Advanced disease <i>David Miles</i>			
10.30-11.00	KEYNOTE LECTURE - Hall 1			
	Personalised breast radiation therapy – Are we there yet? <i>Philip Poortmans</i> Chair: <i>Charlotte Coles</i>			
11.00-11.30	COFFEE			
11.30-12.50	Demystifying partial breast irradiation - Hall 1 Chairs: <i>Charlotte Coles & Philip Poortmans</i>			
	Why and how to do it? <i>Anna Kirby</i> Does it work and who should have it? <i>Charlotte Coles</i> Is less really less? <i>Philip Poortmans</i>			
11.30-12.50	Big Data in Breast Cancer - Hall 5 Chair: <i>David Dodwell & Sophia Turner</i>			
	Introduction: the current UK landscape <i>David Dodwell</i> Invasive Breast Cancer after Screen-detected DCIS in England <i>Gurdeep Mannu</i> Twenty five year risks of breast cancer mortality in 500,000 women <i>Carolyn Taylor</i> Endocrine therapy in the primary care prescription dataset <i>Kieran Horgan</i>			
11.30-12.50	Why can't we kill ER+ breast cancer? - Hall 8 Chairs: <i>Jason Carroll & Stephen Johnston</i>			
	Resistance mechanisms to endocrine therapy <i>Andy Sims</i> Resistance mechanisms to CDK4/6 inhibition <i>Ben O'Leary</i> New prospects for killing ER+ breast cancer cells <i>Matthew Ellis</i>			
11.30-12.50	Managing the side-effects of endocrine therapy - Hall 11 Chairs: <i>Adrienne Morgan & Anne Armstrong</i>			
	Managing the sexual impact of endocrine therapy <i>Isabel White</i> Hot flushes <i>Debbie Fenlon</i> Impact on treatment adherence <i>Mike Dixon</i>			

MONDAY 27TH JANUARY 2020 - FULL PROGRAMME

12.50-14.00	LUNCH & SPONSORED SATELLITE SYMPOSIA	
12.55-13.55	<p>Sponsored symposium: EXACT SCIENCES - Hall 5</p> <p>Prognosis is not enough when making treatment decisions for patients with early breast cancer</p> <p>Chaired by <i>Dr Eric Winer, Director of the Breast Oncology Center, Dana-Farber Cancer Institute, Boston</i></p> <p>Speakers: <i>Dr Mark Harries, Consultant Medical Oncologist, Guy's & St Thomas' NHS FT</i> <i>Dr Mark Verrill, Consultant Medical Oncologist, The Newcastle Upon Tyne Hospitals NHS FT</i> <i>Mr Simon Holt, Consultant Surgical Oncologist, Peony Breast Care Unit, Llanelli</i></p>	PARALLEL SESSIONS
12.55-13.55	<p>Sponsored symposium: ROCHE - Hall 8</p> <p>Immune Checkpoint Inhibition in Metastatic Triple Negative Breast Cancer An interactive educational symposium for healthcare professionals to cover recent advances in metastatic TNBC management and further explore the use of immune checkpoint inhibitors and the management of immunotherapy-related toxicities when treating this disease.</p> <p>Chair: <i>Professor Peter Schmid</i> Speakers: <i>Prof. Javier Cortés & Dr Melissa Phillips</i></p>	
12.55-13.55	<p>Sponsored Symposium: PFIZER - Hall 11</p> <p>Improve Outcomes For Hr+/Her2- Breast Cancer Patients: A Multidisciplinary Case-Based Discussion Welcome and Introduction: <i>Dr Alistair Ring, Consultant Medical Oncologist</i></p> <p>A patient with locally advanced breast cancer: what is the role of Ibrance▼®(palbociclib)? <i>Mr. Henry Cain, Oncoplastic Breast Surgeon</i></p> <p>A patient with metastatic breast cancer, who progressed on adjuvant endocrine treatment: where Ibrance▼®(palbociclib) is now an option <i>Professor Christopher Poole, Consultant Medical Oncologist</i></p> <p>A patient with high burden metastatic breast cancer including visceral metastasis: what factors influence the choice of treatment? <i>Dr. Alistair Ring & Ms. Claire Ryan, Macmillan Nurse Consultant</i></p> <p>Panel discussion</p>	
14.00-14.30	<p>KEYNOTE LECTURE - Hall 1</p> <p>Treatment-dependent breast tumour evolution <i>Matthew Ellis</i> Chair: <i>Sarah Pinder</i></p>	
14.35-15.55	<p>DCIS - Risk estimates and management - Hall 1 Chairs: <i>Sarah Pinder & Lynda Wyld</i></p> <p>Molecular features of DCIS and invasive breast cancer <i>Elinor Sawyer</i> Addressing overtreatment of screen detected DCIS; the LORIS trial <i>Matthew Wallis</i></p> <p><u>Neera Patel Lecture:</u> Breast cancer-related deaths in DCIS: the Dutch experience <i>Jelle Wesseling</i></p>	PARALLEL SESSIONS
14.35-15.55	<p>Special issues in managing metastatic disease - Hall 5 Chairs: <i>Sarah Vinnicombe & Ian Smith</i></p> <p>Patient specific treatment sequencing in ER+ advanced breast cancer <i>Stephen Johnston</i> Whole body MRI in the management of bone metastases <i>Anwar Padhani</i> Is treatment of oligometastases curative? <i>Andreas Makris</i></p>	
14.35-15.55	<p>Phenotypic and genotypic heterogeneity - Hall 8 Chairs: <i>Adrian Lee & Julia Gee</i></p> <p>Genomics of invasive lobular breast cancer <i>Christine Desmedt</i> Genomic landscape of breast cancer metastasis and relapse <i>Adrian Lee</i> Molecular evolution of lymph-node spread in early breast cancer - a surgeon's interest <i>Peter Barry</i></p>	
14.35-15.55	<p>Free Communications I - Hall 11 Chairs: <i>Mark Sibbering & Lesley Turner</i></p> <p>1. 10-year results of the International Breast cancer Intervention Study II (IBIS-II) <i>Jack Cuzick et al</i> 2. Ethnicity and the surgical management of early invasive breast cancer in over 137,000 women in England <i>Toral Gathani et al</i> 3. Surgical outcomes following neoadjuvant chemotherapy - a UK national prospective multi-centre cohort study <i>Stuart A McIntosh et al</i> 4. Retesting of receptors status (ER, PR and HER2) and proliferation biomarkers (Ki67 and SPAG5) after receiving neoadjuvant chemotherapy (NACT) should be mandatory to guides the choice of the optimal adjuvant therapy in Breast Cancer (BC) <i>Stephen Chan et al</i> 5. Metabolic reprogramming of ER+ breast cancer cells in response and resistance to the CDK4/6 inhibitor palbociclib <i>Nicla Lorito et al</i></p>	
15.55-16.20	TEA	

MONDAY 27TH JANUARY 2020 - FULL PROGRAMME

16.20-17.40	Managing the axilla - Hall 1 Chairs: <i>Andreas Makris & Mark Sibbering</i>	PARALLEL SESSIONS
	Can we completely avoid axillary surgery for some breast cancer patients? <i>Monica Morrow</i> UK guidelines for management of the axilla post-NAT <i>Julie Doughty</i> Modern role of the radiologist in managing the axilla <i>Anthony Maxwell</i>	
16.20-17.40	Late recurrence in ER+ disease - Hall 5 Chairs: <i>Adrian Lee & Mark Harries</i>	
	Late-recurring ER+ genomic subgroups <i>Carlos Caldas</i> Predicting late recurrence, patient, tissue and circulating factors <i>Nick Turner</i> Preventing late recurrence <i>Ian Smith</i>	
16.20-17.40	Improving breast cancer outcomes by modifying lifestyle - Hall 8 Chairs: <i>Mairead MacKenzie & Liz O'Riordan</i>	
	Obesity and breast cancer risk <i>Annie Anderson</i> Diet before and after a diagnosis of breast cancer and outcome <i>Michelle Harvie</i> Effects of exercise/physical activity on outcomes after a breast cancer diagnosis <i>Anna Campbell</i>	
16.20-17.40	Novel clinical trial design - Hall 11 Chairs: <i>Judith Bliss & Alistair Ring</i>	
	Breast cancer trials: creating designs fit for contemporary questions <i>Judith Bliss</i> Can Bayesian adaptive trials be useful in breast cancer? <i>James Wason</i> Presurgical window studies of novel drugs – what's the end-point? <i>Adrian Harris</i>	
17.45-18.15	KEYNOTE LECTURE introduced by <i>Gill Ross</i> - Hall 1	
	<u>Cridlan Lecture:</u> De-escalation of medical adjuvant therapy <i>Eric Winer</i>	
18.15-19.15	DRINKS RECEPTION AND POSTER JUDGING SESSION 1 IN EXHIBITION HALL 3	

TUESDAY 28TH JANUARY 2020 - AT A GLANCE

8.00 – 9.00	BREAKFAST SESSION: POSTER JUDGING SESSION 2 IN HALL 3			
	HALL 1	HALL 5	HALL 8	HALL 11
9.00-9.30	KEYNOTE LECTURE Successes, disappointments and the future for clinical trials in primary breast cancer			
9.35-10.55	Modernising Breast MDT Meetings	Immune therapy	Modelling breast cancer - moving closer to the clinic	Trials in progress
10.55-11.20	COFFEE			
11.20-11.50	KEYNOTE LECTURE Genetics and breast cancer risk			
11.55-13.10	Breast cancer risk and prevention	Prognostic and predictive profiling	Special issues in managing young patients	Free Communications II
13.10-14.20	LUNCH & SPONSORED SATELLITE SYMPOSIA			
13.15-14.15		Sponsored symposium: NANOSTRING	Sponsored symposium: LILLY	Sponsored symposium: DAIICHI SANKYO
14.20-14.25	PRIZE PRESENTATIONS			
14.25-14.55	KEYNOTE LECTURE De-escalating surgery for breast cancer			
15.00-16.20	Minimising mastectomy	Special issues for elderly patients	Translating new therapeutic opportunities	Young clinical leaders
				Dragon's Den
16.25-16.55	KEYNOTE LECTURE			
16.55	CLOSE			

TUESDAY 28TH JANUARY 2020 - FULL PROGRAMME

8.00 – 9.00	BREAKFAST SESSION: POSTER JUDGING SESSION 2 IN HALL 3		
9.00-9.30	KEYNOTE LECTURE - Hall 1		
	Successes, disappointments and the future for clinical trials in primary breast cancer <i>Martine Piccart</i> Chair: <i>Judith Bliss</i>		
9.35-10.55	Modernising Breast MDT Meetings - Hall 1 Chairs: <i>Debbie Fenlon & Mark Sibbering</i>		PARALLEL SESSIONS
	Improving MDTM efficiency – the development of a multidisciplinary toolkit <i>Mark Sibbering</i> Multidisciplinary Panel Discussion <i>Sarah Vinnicombe, Sarah Pinder, Charlotte Coles, Katy Hogben, Andrew Wardley & Sue Holcombe</i> Interactive MDT Case Discussions <i>Nicola Roche</i>		
9.35-10.55	Immune therapy - Hall 5 Chairs: <i>Adrienne Morgan & Andrew Tutt</i>		
	Treatment response and toxicities in breast cancer <i>Mark Harries</i> Combined analysis of PDL1 and TILs in Breast Cancer: the new narrative in daily practice? <i>Roberto Salgado</i> Characterising immune response <i>Raza Ali</i>		
9.35-10.55	Modelling breast cancer - moving closer to the clinic - Hall 8 Chairs: <i>Rob Clarke & Ingunn Holen</i>		
	Hormones and breast cancer - why models matter <i>Cathrin Briskin</i> A new 3D model for breast cancer - alternative to xenografts and PDX <i>Gillian Farnie</i> The challenges of measuring the response to immunotherapies in vivo <i>Jonas Nillson</i>		
9.35-10.55	Trials in progress - Hall 11 Chairs: <i>Dan Rea & Carlo Palmieri</i>		
	Multidisciplinary aspects of clinical trials		
	SMALL <i>Nisha Sharma</i> POSNOC and ATNEC <i>Duncan Wheatley</i> PRIMETIME <i>Cliona Kirwan</i> OPTIMA <i>Andreas Makris</i> POETIC -A <i>Dr Alistair Ring</i>		
10.55-11.20	COFFEE		
11.20-11.50	KEYNOTE LECTURE - Hall 1		
	Genetics and breast cancer risk <i>Judy Garber</i> Chair: <i>Trevor Powles</i>		
11.55-13.10	Breast cancer risk and prevention - Hall 1 Chairs: <i>Trevor Powles & Anne Armstrong</i>		PARALLEL SESSIONS
	Recent lessons from the WHI study <i>Rowan Chlebowski</i> Chemoprevention of breast cancer – where have we got to? <i>Jack Cuzick</i> Low-dose tamoxifen for breast cancer prevention <i>Andrea De Censi</i>		
11.55-13.10	Prognostic and predictive profiling - Hall 5 Chairs: <i>Kieran Horgan & Steffi Oesterreich</i>		
	PREDICT vs NPI <i>Paul Pharoah</i> Can mRNA replace IHC for ER? <i>Adrian Lee</i> Ki67 - will it ever make it? A report of 10 years' work from the International Ki67 in Breast Cancer Working Group <i>Mitch Dowsett</i>		
11.55-13.10	Special issues in managing young patients - Hall 8 Chairs: <i>Andrew Wardley & Liz O'Riordan</i>		
	Choosing endocrine treatment <i>Dan Rea</i> Managing fertility in breast cancer <i>Melanie Davies</i> Pregnancy after breast cancer <i>Sibylle Loibl</i>		
11.55-13.10	Free Communications II - Hall 11 Chairs: <i>Andy Sims & David Miles</i>		
	1. Pathological features and outcome of screen detected ductal carcinoma in situ (DCIS): Updated analysis from the UK Sloane Project <i>Abeer M Shaaban et al</i> 2. Fulvestrant plus capivasertib versus placebo in metastatic ER positive breast cancer (FAKTION): A randomised, double-blind, placebo-controlled, phase II trial <i>Sacha Howell et al</i> 3. Results from plasmaMATCH: A multiple parallel cohort, multi-centre clinical trial of circulating tumour DNA testing to direct targeted therapies in patients with advanced breast cancer <i>Alistair Ring et al</i> 4. Whole-genome-sequencing of triple negative breast cancers in a standard population-based clinical setting <i>Johan Staaf et al</i> 5. A 3D-printed electrochemical sensor for measuring reactive oxygen/nitrogen species production from breast cancer cells and ex vivo-cultured tumour tissue <i>William E Jones et al</i>		
13.10-14.20	LUNCH & SPONSORED SATELLITE SYMPOSIA		

TUESDAY 28TH JANUARY 2020 - FULL PROGRAMME

13.15-14.15	Sponsored symposium: NANOSTRING - Hall 5 Identifying Breast Cancer Biomarkers for Understanding Heterogeneity of Response Using the NanoString nCounter® and GeoMx™ DSP platforms to advance breast cancer research <i>Speaker: Rudy van Eijdsen, Senior Product Application Scientist NanoString</i> Investigating the immune landscape of chemotherapy resistant early breast cancers <i>Speaker: Dr Sheeba Irshad, CRUK Clinician Scientist & Honorary Medical Oncologist Guy's Hospital King's College London, UK</i>	PARALLEL SESSIONS
13.15-14.15	Sponsored symposium: LILLY - Hall 8 Chair: Dr Marina Parton Panel: Professor David Cameron, Suzanne Frank, Dr Judy King, Maria Noblet, Dr Duncan Wheatley Welcome and introduction Overview of the mBC treatment landscape and emergence of CDK4/6 inhibitors <i>Dr Marina Parton (Chair)</i> A case in point: benefit in bone metastases* - Case presentation, audience voting and panel discussion <i>Dr Judy King</i> A case in point: leveraging CDK4 & 6 inhibitors in liver lesions* - Case presentation, audience voting and panel discussion <i>Professor David Cameron</i> A case in point: defying primary endocrine resistance* - Case presentation, audience voting and panel discussion Abemaciclib overall survival data presentation <i>Dr Duncan Wheatley</i> Summary and close <i>Dr Marina Parton (Chair)</i> *Educational topics including scheduling treatments and managing toxicities discussed within the case studies.	
13.15-14.15	Sponsored symposium: DAIICHI SANKYO - Hall 11 Challenges in Biomarker interpretation in the Real World – An MDT discussion Panelists: <i>Professor Dan Rea (chair), Dr Rebecca Roylance, Mr Stuart McIntosh, Dr Abeer Shaaban, Professor Christopher Poole</i>	
14.20-14.25	PRIZE PRESENTATIONS - Hall 1	
14.25-14.55	KEYNOTE LECTURE - Hall 1 De-escalating surgery for breast cancer <i>Monica Morrow</i> Chair: <i>Julie Doughty</i>	
15.00-16.20	Minimising mastectomy - Hall 1 <i>Chairs: Andreas Makris & Julie Doughty</i> Neoadjuvant chemotherapy <i>Sibylle Loibl</i> Breast conserving surgery for multifocal tumours <i>Mike Dixon</i> Oncoplastic surgery <i>Katy Hogben</i>	PARALLEL SESSIONS
15.00-16.20	Special issues for elderly patients - Hall 5 <i>Chairs: KL Cheung & Alistair Ring</i> Overview of issues <i>KL Cheung</i> Bridging the Age Gap <i>Lynda Wyld</i> Dementia and decision making <i>Yasmin Jauhari</i>	
15.00-16.20	Translating new therapeutic opportunities - Hall 8 <i>Chairs: Rob Clarke & Adrian Harris</i> Targeting CDK7 in ER+ breast cancer <i>Simak Ali</i> Androgen receptor agonists for AR+ disease <i>Carlo Palmieri</i> Prospects for targeting FOXA1 <i>Jason Carroll</i>	
15.00-16.20	Young clinical leaders - Hall 11 <i>Chairs: Cliona Kirwan & Ellen Copson</i> Trainee collaborative research - a successful new story <i>Cliona Kirwan</i> The achievements of the Mammary Fold Collaborative and current projects <i>Lisa Sheehan</i> Multidisciplinary collaboration – Introduction to the BCTRCG <i>Ellen Copson</i> Dragon's Den <i>Tim Robinson, Sheeba Irshad, Teo PeiJing</i> Academic Career Pathways <i>Cliona Kirwan</i> Why and How to join a Trial Management Group <i>Indrani Bhattacharya</i>	
16.25-16.55	KEYNOTE LECTURE - Hall 1 Collaborative trials - Better Together <i>David Cameron</i> Chair: <i>Mitch Dowsett</i>	
16.55	CLOSE	

This event is hosted by:



In partnership with:



British Breast Group



UK IBCS Satellite Symposium 2020

Immune Checkpoint Inhibition in Metastatic Triple Negative Breast Cancer (mTNBC)

Monday 27th January 2020

Hall 8

12:55 - 13:55

Expert speakers:

Professor Peter Schmid, Dr Javier Cortés, Dr Melissa Phillips

This symposium is organised and funded by Roche Products Limited | For healthcare professionals only

Roche Resources

Aims to give UK healthcare professionals quick and easy access to information that supports clinical practice

www.rocheresources.co.uk

Looking for information for your clinical practice?

Discover more at Roche Resources - a 'one-stop' online resource for all healthcare professionals looking for medical services and information about Roche medicines.

- Find a growing wealth of information about our medicines and the therapy areas in which these are used
- Identify resources to use with your colleagues and your patients
- Keep up-to-date with the latest news from national and international Congresses
- Available online 24/7.

Discover more at
www.rocheresources.co.uk

Scan the QR code with your device camera or visit
www.rocheresources.co.uk
to find out more



Scan me

Platinum sponsors



**EXACT
SCIENCES**

Genomic health Uk. Ltd. is
now Exact Sciences UK. Ltd

Lilly

nanoString®



Gold Sponsor:



Exhibitors:

Association of Breast Surgery
Breast Cancer Now and Breast Cancer Care
Eisai • Igea Medical • Micrima • NABCOP
Napp Pharmaceuticals • Novartis • Pierre Fabre • Samantree Medical
The Age Gap Study • Sysmex • Takeda